ES2149347T3 - Composiciones farmaceuticas de verotoxinas y tratamientos medicos con las mismas. - Google Patents

Composiciones farmaceuticas de verotoxinas y tratamientos medicos con las mismas.

Info

Publication number
ES2149347T3
ES2149347T3 ES95908853T ES95908853T ES2149347T3 ES 2149347 T3 ES2149347 T3 ES 2149347T3 ES 95908853 T ES95908853 T ES 95908853T ES 95908853 T ES95908853 T ES 95908853T ES 2149347 T3 ES2149347 T3 ES 2149347T3
Authority
ES
Spain
Prior art keywords
verotoxins
pharmaceutical compositions
same
medical treatments
verotoxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95908853T
Other languages
English (en)
Inventor
Clifford A Lingwood
Richard Hill
Hannah Farkas-Himsley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GEVA RUTH EXECUTOR FOR DEC
KROYANKER LEORAH EXECUTOR FOR
Original Assignee
GEVA RUTH EXECUTOR FOR DEC
KROYANKER LEORAH EXECUTOR FOR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GEVA RUTH EXECUTOR FOR DEC, KROYANKER LEORAH EXECUTOR FOR filed Critical GEVA RUTH EXECUTOR FOR DEC
Application granted granted Critical
Publication of ES2149347T3 publication Critical patent/ES2149347T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

SE HA DESCRITO QUE LAS COMPOSICIONES FARMACEUTICAS CON VEROTOXINAS CONOCIDAS, EN PARTICULAR LA VEROTOXINA 1, RESULTAN UTILES PARA EL TRATAMIENTO DE LAS NEOPLASIAS DE MAMIFEROS, EN ESPECIAL EL CANCER DE OVARIOS Y EL CANCER DE PIEL. SORPRENDENTEMENTE, A PESAR DE QUE LA ACTIVIDAD ANTINEOPLASICA DE LA VEROTOXINA 1 SE HABIA DEMOSTRADO PREVIAMENTE IN VITRO, SE HA DEMOSTRADO QUE DOSIS NO LETALES DE VEROTOXINA 1 SON TERAPEUTICAMENTE ANTINEOPLASICAS IN VIVO.
ES95908853T 1994-02-22 1995-02-20 Composiciones farmaceuticas de verotoxinas y tratamientos medicos con las mismas. Expired - Lifetime ES2149347T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002116179A CA2116179C (en) 1994-02-22 1994-02-22 Verotoxin pharmaceutical compositions and medical treatments therewith

Publications (1)

Publication Number Publication Date
ES2149347T3 true ES2149347T3 (es) 2000-11-01

Family

ID=4152948

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95908853T Expired - Lifetime ES2149347T3 (es) 1994-02-22 1995-02-20 Composiciones farmaceuticas de verotoxinas y tratamientos medicos con las mismas.

Country Status (10)

Country Link
US (1) US6228370B1 (es)
EP (1) EP0746337B1 (es)
JP (1) JPH10500103A (es)
AT (1) ATE193451T1 (es)
AU (1) AU701100B2 (es)
CA (1) CA2116179C (es)
DE (1) DE69517302T2 (es)
ES (1) ES2149347T3 (es)
NZ (1) NZ331165A (es)
WO (1) WO1995022349A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835710B1 (en) * 1994-02-22 2004-12-28 Hsc Research & Development Limited Partnership Verotoxin pharmaceutical compositions and medical treatments therewith
AU7348998A (en) * 1997-05-16 1998-12-08 Hospital For Sick Children, The Inhibition of angiogenesis by verotoxins
AU748852B2 (en) 1998-05-20 2002-06-13 Pdl Biopharma, Inc. Humanized antibodies that recognize verotoxin II and cell line producing same
WO2000061183A2 (en) * 1999-04-09 2000-10-19 Hsc Research And Development Limited Partnership Verotoxin treatment of lymphomas
AU4691700A (en) * 1999-05-03 2000-11-17 Governors Of The University Of Alberta, The Shiga-like toxin as an enriching and purging agent
AU2003208097A1 (en) 2002-02-04 2003-09-02 Hideo Yoshida Anticancer agents using vero toxin variants

Also Published As

Publication number Publication date
WO1995022349A1 (en) 1995-08-24
JPH10500103A (ja) 1998-01-06
EP0746337A1 (en) 1996-12-11
AU701100B2 (en) 1999-01-21
EP0746337B1 (en) 2000-05-31
DE69517302T2 (de) 2001-01-18
DE69517302D1 (de) 2000-07-06
CA2116179A1 (en) 1995-08-23
AU1703195A (en) 1995-09-04
US6228370B1 (en) 2001-05-08
CA2116179C (en) 2008-01-08
ATE193451T1 (de) 2000-06-15
NZ331165A (en) 2000-01-28

Similar Documents

Publication Publication Date Title
CY1121447T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης
ATE80790T1 (de) Zusammensetzung zur behandlung der haut.
PT933995E (pt) Metodo para tratamento de lesao endotelial
CY1105818T1 (el) Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
DE60124715D1 (de) Er produktion von beta-endorphin
ATE106743T1 (de) Fgf enthaltende stabilisierte zubereitungen.
SE9701161D0 (sv) New use I
ATE77230T1 (de) Melatoninhaltige mittel sowie deren verwendungen.
ATE162804T1 (de) Selbstvernetztes gellangummi
ES2149347T3 (es) Composiciones farmaceuticas de verotoxinas y tratamientos medicos con las mismas.
ATE340561T1 (de) Verwendung von antiseptika zur herstellung von arzneimitteln zur prophylaxe und behandlung von entzündungen im korperinneren des menschen
CA2351947A1 (en) Hyperforin as cytostatic agent and hyperforin ointment or cream as application form
MX9203405A (es) Compuestos activos para usarse en el tratamiento de tumores.
GB9509888D0 (en) Terpenoidic derivatives useful as antitumour agents
ATE128964T1 (de) Anwendung von beta-alethin in zellkultur und therapie.
CA2163716A1 (en) Verotoxin pharmaceutical compositions and medical treatments therewith
ATE141510T1 (de) Arzneimittel enthaltend cd14
ATE83657T1 (de) Pharmazeutische zusammensetzung.
FR2644459B1 (fr) Esters retinoiques de l-cladinose, leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
RU94024337A (ru) Антиметастатическое средство
PT1150981E (pt) Composto nucleosidico terapeutico
IT1265649B1 (it) Prodotto dermatologico per uso topico, relativo processo di produzione ed ulizzazione terapeutica nelle ustioni e patologie cutanee.
UA19504A (uk) Засіб для лікуваhhя гhійhих запалеhь шкіри та підшкірhої клітковиhи
IT8919802A0 (it) Composto utile per il trattamento terapeutico e la profilassi nella patologia cutanea fotocondizionata.
UA23985A (uk) Спосіб лікуваhhя запальhих захворюваhь вhутрішhіх геhіталій у дівчат та підлітків

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 746337

Country of ref document: ES